Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y302-01096 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-734 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-47 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate |
2019-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a95abd3384c10a50a1e3ee626ef73cf6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_907927cad6f91fae625ebc2eb45cec32 |
publicationDate |
2019-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2019352394-A1 |
titleOfInvention |
Enzymatic modification of anti-aqp4 autoantibody for modulating neuromyelitis optica |
abstract |
Provided herein is a method of treating neuromyelitis optica (NMO) in an animal or human subject comprising administering to the subject a composition comprising a therapeutically effective amount of an Fc region modified anti-AQP4 antibody, thereby treating the NMO in the subject. In some embodiments, the Fc region modified anti-AQP4 antibody is an anti-AQP4 antibody deglycosylated at the amino acid position Asn297. In other embodiments, the Fc region modified anti-AQP4 antibody is an anti-AQP4 antibody F(ab′) 2 fragment. |
priorityDate |
2012-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |